Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Dengue virus serotype 4 envelope protein (E protein) is a structural glycoprotein on the viral surface, organized into three domains (EDI, EDII, EDIII) that form homodimers in a herringbone pattern on the mature virion. It mediates receptor binding, endocytosis, and low-pH-induced conformational changes for membrane fusion in host endosomes, with EDII exposing a fusion loop and hinge region critical for these processes. The protein is the primary target of neutralizing antibodies post-infection or vaccination, though domain-specific epitopes influence serotype cross-reactivity and antibody responses.[1][2][3][7][13]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue virus serotype 4 envelope protein (DENV-4 E protein).